Search hospitals
>
Tennessee
>
Chattanooga
SCRI Tennessee Oncology Chattanooga
Claim this profile
Chattanooga, Tennessee 37404
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Bladder Cancer
56 reported clinical trials
3 medical researchers
Summary
SCRI Tennessee Oncology Chattanooga is a medical facility located in Chattanooga, Tennessee. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Bladder Cancer and other specialties. SCRI Tennessee Oncology Chattanooga is involved with conducting 56 clinical trials across 54 conditions. There are 3 research doctors associated with this hospital, such as Edward Arrowsmith, Edward Riker Arrowsmith, MD, and Anz III Bertrand.
Area of expertise
Lung Cancer
SCRI Tennessee Oncology Chattanooga has run 16 trials for Lung Cancer. Some of their research focus areas include:
Breast Cancer
SCRI Tennessee Oncology Chattanooga has run 15 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Edward Arrowsmith
SCRI - Tennessee Oncology Chattanooga
6 years of reported clinical research
Edward Riker Arrowsmith, MD
Tennessee Oncology Chattanooga-SCRI
3 years of reported clinical research
Anz III Bertrand
Tennessee Oncology, PLLC
5 years of reported clinical research
Clinical Trials running at SCRI Tennessee Oncology Chattanooga
Follicular Lymphoma
Chronic Lymphocytic Leukemia
Endometrial Cancer
Colorectal Cancer
Ovarian Cancer
Cancer
Pancreatic Cancer
Non-Hodgkin's Lymphoma
Hereditary Sensory Neuropathy
Acinar Cell Carcinoma
Tazemetostat + Lenalidomide + Rituximab
for Follicular Lymphoma
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.
Recruiting
1 award
Phase 3
4 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at SCRI Tennessee Oncology Chattanooga?
SCRI Tennessee Oncology Chattanooga is a medical facility located in Chattanooga, Tennessee. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Bladder Cancer and other specialties. SCRI Tennessee Oncology Chattanooga is involved with conducting 56 clinical trials across 54 conditions. There are 3 research doctors associated with this hospital, such as Edward Arrowsmith, Edward Riker Arrowsmith, MD, and Anz III Bertrand.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.